Pharmabcine

Developer of monoclonal antibodies for the treatment of cancer and inflammatory diseases

placeDaejeon, Daejeon, South Korea calendar_todayFounded 2008 groups48 employees language pharmabcine.com

Innovation

25 patent families (10 granted) — focus: Chemistry & metallurgy, Human necessities, Physics & computing; filing pace slowing. Cited 1,015 times.

YearFilings
20142
20153
20168
20175
20185
20194
20206
20218
20227
20238
20245
20255

Investor mix

19 investors on record; lead investors include Novartis Venture Fund, Korea-Seoul Life Science Fund, Tongyang, Mirae Asset Venture.

Investor typeCountShare
Venture capital1474%
Private equity15%
Other / undisclosed421%
Coming soon